醋酸格拉替雷诱导的急性肝炎。
Acute hepatitis induced by glatiramer acetate.
作者信息
Deltenre Pierre, Peny Marie-Odile, Dufour André, Nady Mohamed El, Henrion Jean
机构信息
Hopital de Jolimont, Service d'Hépato-gastroentérologie, Rue Ferrer, 159, Haine-Saint-Paul, 7100, Belgium.
出版信息
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.09.2008.0913. Epub 2009 Feb 27.
Abstract
Glatiramer acetate, a mixture of synthetic polypeptides able to prevent autoimmune encephalomyelitis in experimental models, is used as a treatment for patients with active relapsing-remitting multiple sclerosis. We report one case of glatiramer acetate induced hepatitis. Liver biopsy was consistent with a diagnosis of drug induced hepatitis and alanine aminotransferase returned to normal values after treatment discontinuation. The present case should serve as a warning that glatiramer acetate may cause acute liver disease.
摘要
醋酸格拉替雷是一种合成多肽混合物，在实验模型中能够预防自身免疫性脑脊髓炎，被用作活动性复发缓解型多发性硬化症患者的治疗药物。我们报告了一例醋酸格拉替雷诱发肝炎的病例。肝活检结果符合药物性肝炎的诊断，停用治疗药物后丙氨酸转氨酶恢复到正常水平。本病例应作为一个警示，即醋酸格拉替雷可能会引起急性肝病。
相似文献
1
Acute hepatitis induced by glatiramer acetate.醋酸格拉替雷诱导的急性肝炎。
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.09.2008.0913. Epub 2009 Feb 27.
2
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.一名年轻女性多发性硬化症患者发生醋酸格拉替雷诱导的肝炎。
Mult Scler Relat Disord. 2014 Nov;3(6):732-4. doi: 10.1016/j.msard.2014.08.001. Epub 2014 Aug 15.
3
Glatiramer acetate induced hepatotoxicity.醋酸格拉替雷诱导的肝毒性。
Curr Drug Saf. 2012 Apr;7(2):186-8. doi: 10.2174/157488612802715690.
4
Risk-benefit assessment of glatiramer acetate in multiple sclerosis.醋酸格拉替雷治疗多发性硬化症的风险效益评估。
Drug Saf. 2001;24(13):979-90. doi: 10.2165/00002018-200124130-00005.
5
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.皮下注射干扰素β-1a与醋酸格拉替雷治疗复发型多发性硬化症的比较（复发型多发性硬化症中重组人干扰素β-1a对比醋酸格拉替雷[REGARD]研究）：一项多中心、随机、平行、开放标签试验。
Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.
6
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.醋酸格拉替雷治疗多发性硬化症：作用机制的新观点。
CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000.
7
Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.醋酸格拉替雷：复发缓解型多发性硬化症治疗应用综述
CNS Drugs. 2002;16(12):825-50. doi: 10.2165/00023210-200216120-00004.
8
Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.聚焦醋酸格拉替雷在复发缓解型多发性硬化症中的应用
BioDrugs. 2003;17(3):207-10. doi: 10.2165/00063030-200317030-00007.
9
Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.口服醋酸格拉替雷对复发型多发性硬化症患者临床及MRI监测的疾病活动的影响：一项多中心、双盲、随机、安慰剂对照研究
Lancet Neurol. 2006 Mar;5(3):213-20. doi: 10.1016/S1474-4422(06)70327-1.
10
Does glatiramer acetate provoke hepatitis in multiple sclerosis?
Mult Scler Relat Disord. 2014 Mar;3(2):266-8. doi: 10.1016/j.msard.2013.09.008. Epub 2013 Oct 8.
引用本文的文献
1
Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database.基于FAERS数据库的药物性自身免疫性肝炎真实世界药物警戒研究
Sci Rep. 2025 Feb 8;15(1):4783. doi: 10.1038/s41598-025-89272-x.
2
Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility.用于多发性硬化症的药物的肝毒性、诊断挑战以及 HLA 基因型易感性的作用。
Int J Mol Sci. 2023 Jan 3;24(1):852. doi: 10.3390/ijms24010852.
3
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.《复发缓解型多发性硬化症及其肝损伤的疾病修饰治疗：叙事性综述》。
CNS Drugs. 2021 Aug;35(8):861-880. doi: 10.1007/s40263-021-00842-9. Epub 2021 Jul 28.
4
Liver injury and glatiramer acetate, an uncommon association: case report and literature review.肝脏损伤与醋酸格拉替雷，一种罕见的关联：病例报告及文献综述
Ther Adv Neurol Disord. 2017 Nov;10(11):367-372. doi: 10.1177/1756285617722352. Epub 2017 Jul 26.
5
Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report.醋酸格拉替雷用于治疗多发性硬化症引起的药物性肝损伤：一例报告
J Investig Med High Impact Case Rep. 2013 Dec 17;1(4):2324709613517493. doi: 10.1177/2324709613517493. eCollection 2013 Oct-Dec.
6
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.醋酸格拉替雷致青少年 MS 患者急性肝毒性
Neurology. 2013 Aug 27;81(9):850-2. doi: 10.1212/WNL.0b013e3182a2cc4a. Epub 2013 Jul 24.
本文引用的文献
1
Glatiramer acetate: mechanisms of action in multiple sclerosis.醋酸格拉替雷：在多发性硬化症中的作用机制
Autoimmun Rev. 2007 Aug;6(7):469-75. doi: 10.1016/j.autrev.2007.02.003. Epub 2007 Mar 6.
2
Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.醋酸格拉替雷在一名多发性硬化症患者中诱发自身免疫性肝炎急性加重。
J Neurol. 2007 Jun;254(6):816-7. doi: 10.1007/s00415-006-0441-3. Epub 2007 Mar 12.
3
Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.接受醋酸格拉替雷治疗的多发性硬化症患者并发自身免疫性甲状腺功能亢进——病例报告
Eur J Neurol. 2001 Mar;8(2):199. doi: 10.1046/j.1468-1331.2001.00196.x.
4
Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.一名多发性硬化症患者在接受醋酸格拉替雷治疗期间发生重症肌无力。
J Neurol. 2000 Sep;247(9):713. doi: 10.1007/s004150070118.
5
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.共聚体1可诱导与髓鞘碱性蛋白发生交叉反应的2型辅助性T细胞，并抑制实验性自身免疫性脑脊髓炎。
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10821-6. doi: 10.1073/pnas.94.20.10821.
Zotero 插件